Search Results

The product title you are looking for is no longer available. Other similar products that may interest you are listed below:

Refine your Search

Results for 'Pain Therapeutics Inc -Financial Company Report'
Title Publication Date Price Relevance
Pain Therapeutics Inc-Therapeutic Competitors Mar 2011 £220 100%
Pain Therapeutics Inc-Detailed Product Pipeline Mar 2011 £475 99%
Pain Therapeutics, Inc. - SWOT Analysis Sep 2011 £79 99%
Pain Therapeutics, Inc. – Product Pipeline Review
H2 2011
 Nov 2011 £315 97%
Acute Pain Global Clinical Trials Review
Q1, 2011
 Jan 2011 £630 94%
Pain Global Clinical Trials Review
Q1, 2011
 Jan 2011 £630 94%
Chronic Pain Therapeutics
Pipeline Assessment and Market Forecasts to 2017
 Apr 2011 £1,265 94%
Chronic Pain - Pipeline Review
H2 2011
 Aug 2011 £315 94%
Dental Pain Global Clinical Trials Review
Q1, 2011
 Mar 2011 £630 94%
Neuropathic Pain - Pipeline Review
H2 2011
 Sep 2011 £315 94%
Chronic Pain Global Clinical Trials Review
Q1, 2011
 Jan 2011 £630 94%
Cancer Pain - Pipeline Review
H2 2011
 Oct 2011 £315 94%
Musculoskeletal Pain - Pipeline Review
H2 2011
 Oct 2011 £315 94%
Neuropathic Pain Global Clinical Trials Review
Q1, 2011
 Jan 2011 £630 94%
Neuropathic Pain Therapeutics
Pipeline Assessment and Market Forecasts to 2018
 Sep 2011 £2,215 94%
Joint Pain Global Clinical Trials Review
H2, 2011
 Nov 2011 £630 93%
Inflammatory Pain Global Clinical Trials Review
Q1, 2011
 Mar 2011 £630 93%
Acute Pain Therapeutics
Pipeline Assessment and Market Forecasts to 2017
 Mar 2011 £1,265 93%
Cancer Pain Global Clinical Trials Review
Q1, 2011
 Feb 2011 £630 93%
Osteoarthritis Pain Therapeutics
Pipeline Assessment and Market Forecasts to 2017
 May 2011 £1,265 93%
Renal Pain Global Clinical Trials Review
H2, 2011
 Nov 2011 £630 93%
Sciatic Pain - Pipeline Review
H2 2011
 Nov 2011 £315 93%
Cancer Pain Therapeutics
Pipeline Assessment and Market Forecasts to 2017
 Apr 2011 £1,265 93%
Post-Operative Pain – Pipeline Review
H2 2011
 Dec 2011 £315 93%
Acute Pain - Pipeline Review
H2 2011
 Sep 2011 £315 93%
Back Pain - Pipeline Review
H2 2011
 Oct 2011 £315 92%
Chronic Pain - Pipeline Review
Q2 2011
 Apr 2011 £315 92%
The Future of Pain Management Therapeutics, Analysis and Market Forecasts to 2016
Increasing Generic Competition Creates Challenges
 Mar 2010 £2,215 92%
Ocular Pain - Pipeline Review
H2 2011
 Nov 2011 £315 91%
Neuropathic Pain
Drug Pipeline Analysis and Market Forecasts to 2015
 Dec 2009 £1,265 91%